Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells

Prostate cancer (PCa) is the second most common malignancy and is the fifth leading cause of cancer mortality among men globally. Docetaxel‐based therapy remains the first‐line treatment for metastatic castration‐resistant prostate cancer. However, dose‐limiting toxicity including neutropenia, myelo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalairndran, Geetha, Chung, Ivy, Abdul Razack, Azad Hassan, Chung, Felicia Fei‐Lei, Hii, Ling‐Wei, Lim, Wei‐Meng, Looi, Chin King, Mai, Chun‐Wai, Leong, Chee‐Onn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419172/
https://www.ncbi.nlm.nih.gov/pubmed/34322995
http://dx.doi.org/10.1111/jcmm.16684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419172/
https://www.ncbi.nlm.nih.gov/pubmed/34322995
http://dx.doi.org/10.1111/jcmm.16684

Ejemplares similares